PolyPeptide Group (SWX:PPGN) Stock Price Ignores Margin Momentum Under 44 Offer

PolyPeptide Group’s share price closed at CHF44 on Thursday, exactly where Samsung Biologics has pitched its all cash tender offer at CHF44.31. The market is trading the stock as if the deal price already tells the whole story. The earnings print suggests a different perspective.

The key development is the rise in profitability. Revenue in the first half of 2026 reached €236.6m and earnings before interest, tax, depreciation and amortisation were €49.1m, with an underlying margin near 19%. For a contract drug manufacturing specialist, that margin shift is now a central factor for investors to weigh against the influence of the takeover terms on the share price.

Is PolyPeptide Group now priced for a smooth path to profitability, or is the current CHF44 offer already baking in too much optimism? Compare the takeover premium, growth forecasts and cash flow assumptions using the valuation analysis for PolyPeptide Group

H1 2026 Earnings Summary

• Revenue H1 2026 vs. H1 2025: €236.6m vs. €167.1m (up 41.6%)
• Net Income H1 2026 vs. H1 2025: Not disclosed for H1 2026 vs. loss of €26.5m (directional improvement not quantifiable from reported figures)
• Basic EPS H1 2026 vs. H1 2025: Not disclosed for H1 2026 vs. loss per share of €0.80 (directional improvement not quantifiable from reported figures)
• EBITDA Margin H1 2026 vs. H1 2025: 20.7% reported margin in H1 2026 vs. not disclosed for H1 2025, with underlying H1 2026 EBITDA margin around 18.9% after adjusting for one off items

Prefer clean charts instead of another wall of earnings tables and deal headlines? See how PolyPeptide Group’s profitability shift fits into its overall financial picture in an interactive visual format with the company report for PolyPeptide Group.

PolyPeptide bull case hinges on structural profitability

Bulls argue PolyPeptide Group is turning high metabolic exposure and new capacity into a structurally higher earnings base rather than a one off spike. The H1 2026 print gives that view real, but not complete, support. Revenue of €236.6m with a reported 20.7% EBITDA margin and roughly 18.9% underlying margin shows the Braine large scale plant is now running at high utilization with better yields. Metabolic therapeutics now contribute about 68% of revenue and grew far faster than the group, which aligns with the thesis that late stage obesity programs are converting into meaningful commercial volumes. Upgraded 2026 revenue growth and margin guidance, while keeping CapEx at 15 to 20% of sales, suggests management sees current efficiency as repeatable. The key bullish milestone still ahead is successful ramp and utilization of Strasbourg and Malmö while maintaining margins near current levels.

Bear case focuses on concentration and deal driven pricing

Bears worry that PolyPeptide Group is leaning heavily on one therapeutic pocket and that investors are paying more for takeover optionality than for cash flows. The H1 mix supports the concentration concern. Roughly 68% of revenue now comes from metabolic therapeutics and Braine is already at target utilization, so any slowdown or pricing pressure in that area would quickly show up in earnings. Management also confirms that Malmö expansion relies heavily on a major metabolic partner and only starts ramping in 2027, which delays proof that new capacity will be fully used. On valuation risk, the share price has settled at CHF44 where the Samsung Biologics offer is pitched, and short term returns are flat, which suggests the market is now treating the tender price as the reference point rather than the earnings path.

Compare how PolyPeptide Group’s margin ambitions and capacity ramp stack up against current Street expectations, and see whether analysts think the CHF44 price already reflects the earnings story with the consensus price target analysis for PolyPeptide Group

Stay Ahead With Simply Wall St

If PolyPeptide Group’s rising margins and takeover offer have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the earnings story evolves. Once you decide to take a position, use the Portfolio Command Center to cut through day to day noise and focus on the updates that matter for your holdings. For a broader view on how other investors are thinking about PolyPeptide Group and similar stocks, turn to the Community to tap into crowd insights. Spot potential catalysts or emerging risks early and keep your decisions a step ahead of the market.

Seeking Alternatives Beyond PolyPeptide Group?

Fresh ideas can move fast. Some stocks are building quiet breakout momentum while they are still under the radar for now. Check them before the crowd catches up and act now.

• Spot resilient balance sheets before they are widely talked about and review the curated list of solid balance sheet and fundamentals stocks (429 results) to see which businesses still look built for durability.
• Ride income streams that could help steady a portfolio and scan the hand picked 444 dividend fortresses while yields and entry prices still look compelling.
• Anticipate the next leg of AI infrastructure demand and filter the focused 55 AI infrastructure stocks while these stocks are still being quietly accumulated.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com